[1] IKENOUE T, HIKIBA Y, KANAI F. Functional analysis of mutations within the kinase activation segment of B-raf in human colorectal tumors. 2003(23)
[2] IKAWA S, FUKUI M, UEYAMA Y. B-raf,a new member of the raf family,is activated by DNA rearrangement, 1988(6)
[3] DAVIES H, BIGNELL G R, COX C. Mutations of the BRAF gene in human cancer. 2002(6892). doi:10.1038/nature00766
[4] MERCER K E, PRITCHARD C A. Raf proteins and cancer:Braf is identified as a mutational target. 2003(1)
[5] MEYER P, SERGI C, GARBE C. Polymorphisms of the BRAF gene predispose males to malignant melanoma, 2003(1)
[6] WOJNOWSKI L, STANCATO L F, LARNER A C. Overlapping and specific functions of B-raf and C-raf-1 proto-oncogenes during mouse embryogenesis. 2000(1). doi:10.1016/S0925-4773(99)00276-2
[7] HUSER M, LUCKETT J, CHILOECHES A. MEK kinase activity is not necessary for Raf-1 function. 2001(8)
[8] MIKULA M, SCHREIBER M, HUSAK Z. Embryonic lethality and fetal liver apoptosis in mice lacking the C-raf-1 gene. 2001(8)
[9] ZHANG B H, GUAN K L. Activation of B-raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. 2000(20)
[10] BONNI A, BRUNET A, WEST A E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. 1999(5443). doi:10.1126/science.286.5443.1358
[11] SMALJEY K S. A pivotal role for ERK in malignant melanoma. 2003(5). doi:10.1002/ijc.10978
[12] HINGORANI S R, JACOBETZ M A, ROBERTSON G P. Suppression of BRAF (V599E) in human melanoma abrogates transformation. 2003(17)
[13] WELLBROCK C, OGILVIE L, HEDLEY D. V599EBRAF is an oncogene in melanocytes. 2004(7). doi:10.1158/0008-5472.CAN-03-3433
[14] KOO H M, van BROCKLIN M, McWILLIAMS M J. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase. 2002(5). doi:10.1073/pnas.052707699
[15] COLLISSON E A, DE A, SUZUKI H. Treatment of metastatic melanoma with an orally available inhibitor of the RasRaf-MAPK cascade. 2003(18)
[16] HOUBEN R, BECKER J C, KAPPEL A. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. 2004(1). doi:10.1186/1477-3163-3-6
[17] YUEN S T, DAVIES H, CHANT L. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. 2002(22)
[18] NAOKI K, CHEN T H, RICHARDS W G. Missense mutations of the BRAF gene in human lung adenocarcinoma. 2002(23)
[19] OLIVEIRA C, PINTO M, DUVAL A. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. 2003(57). doi:10.1038/sj.onc.1207061
[20] NAGASAKA T, SASAMOTO H, NOTOHARA K. Colorectal cancer with mutation in BRAF,KRAS,and wild-type with respect to both oncogenes showing different patterns of DNA methylation. 2004(22). doi:10.1200/JCO.2004.02.154
[21] WANG L, CUNNINGHAM J M, WINTERS J L. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. 2003(17)
[22] FRANSEN K, KLINTENAS M, OSTERSTROM A. Mutation analysis of the BRAF,ARAF and RAF-1 genes in human colorectal adenocarcinomas. 2004(4). doi:10.1093/carcin/bgh049
[23] IKENOUE T, HIKIBA Y, KANAI F. Different effects of point mutations within the B-raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. 2004(10). doi:10.1158/0008-5472.CAN-03-3591
[24] KAMBARA T, SIMMS L A, WHITEHALL V L. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. 2004(8). doi:10.1136/gut.2003.037671
[25] CHANT L, ZHAO W, LEUNG S Y. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. 2003(16)
[26] ISHIMURA N, YAMASAWA K, KARIM-RUMI M A. BRAF and K-ras gene mutations in human pancreatic cancers. 2003(2)
[27] CALHOUN E S, JONES J B, ASHFAQ R. BRAF and FBXW7 (CDC4,FBW7,AGO,SEL10) mutations in distinct subsets of pancreatic cancer:potential therapeutic targets. 2003(4)
[28] WU M, SEMBA S, OUE N. BRAF/K-ras mutation,microsatellite instability,and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. 2004(4). doi:10.1007/s10120-004-0300-9
[29] TANNAPFEL A, SOMMERER F, BENICKE M. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. 2003(5). doi:10.1136/gut.52.5.706
[30] BLAKER H, HELMCHEN B, BONISCH A. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. 2004(8). doi:10.1080/00365520410005847
[31] PERREN A, SCHMID S, LOCHER T. BRAF and endocrine tumors:mutations are frequent in papillary thyroid carcinomas,rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. 2004(4). doi:10.1677/erc.1.00841 |
